-
EP4103249
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4103249
| EP4103249 - EX VIVO METHOD FOR REMOVAL OF RCDP [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 15.08.2025 Database last updated on 26.03.2026 | |
| Former | Request for examination was made Status updated on 18.11.2022 | ||
| Former | The international publication has been made Status updated on 20.08.2021 | ||
| Former | unknown Status updated on 02.03.2021 | Most recent event Tooltip | 19.02.2026 | New entry: Reply to examination report | Applicant(s) | For all designated states NHS Blood & Transplant 500 North Bristol Park Northway, Filton Bristol BS34 7QH / GB | [2022/51] | Inventor(s) | 01 /
ANSTEE, David NHS Blood & Transplant 500 North Bristol Park Northway, Filton Bristol BS34 7QH / GB | 02 /
MANKELOW, Tosti NHS Blood & Transplant 500 North Bristol Park Northway, Filton Bristol BS34 7QH / GB | 03 /
TROMPETER, Sara NHS Blood & Transplant Charcot Road, Colindale London NW9 5BG / GB | [2022/51] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2022/51] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 21706665.3 | 10.02.2021 | [2022/51] | WO2021GB50298 | Priority number, date | GB20200001795 | 10.02.2020 Original published format: GB 202001795 | [2022/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021161007 | Date: | 19.08.2021 | Language: | EN | [2021/33] | Type: | A1 Application with search report | No.: | EP4103249 | Date: | 21.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.08.2021 takes the place of the publication of the European patent application. | [2022/51] | Search report(s) | International search report - published on: | EP | 19.08.2021 | Classification | IPC: | A61M1/38, A61M1/36, B01D15/38, A61K35/16 | [2022/51] | CPC: |
A61M1/38 (EP,US);
A61K35/16 (EP,US);
A61M1/3496 (US);
A61M1/3687 (EP,US);
A61P7/04 (US);
B01D15/3809 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/51] | Title | German: | EX-VIVO-VERFAHREN ZUR ENTFERNUNG VON RCDP | [2022/51] | English: | EX VIVO METHOD FOR REMOVAL OF RCDP | [2022/51] | French: | PROCÉDÉ EX-VIVO POUR L'ÉLIMINATION DE PARTICULES DÉRIVÉES DES GLOBULES ROUGES | [2022/51] | Entry into regional phase | 09.09.2022 | National basic fee paid | 09.09.2022 | Designation fee(s) paid | 09.09.2022 | Examination fee paid | Examination procedure | 09.09.2022 | Examination requested [2022/51] | 09.09.2022 | Date on which the examining division has become responsible | 22.03.2023 | Amendment by applicant (claims and/or description) | 18.08.2025 | Despatch of a communication from the examining division (Time limit: M06) | 17.02.2026 | Reply to a communication from the examining division | Fees paid | Renewal fee | 16.02.2023 | Renewal fee patent year 03 | 07.02.2024 | Renewal fee patent year 04 | 17.02.2025 | Renewal fee patent year 05 | 16.02.2026 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A] JP2019215341 (LSI MEDIENCE CORP et al.) | [XI] VAN DEN GOOR ET AL: "Cell Saver device efficiently removes cell-derived microparticles during cardiac surgery", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 134, no. 3, 25 August 2007 (2007-08-25), pages 798 - 799, XP022204937, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2007.02.042 DOI: http://dx.doi.org/10.1016/j.jtcvs.2007.02.042 | [XPI] SMITH R ET AL: "Removal of red cell-derived membrane particles from the plasma of sickle cell patients during apheresis could reduce their hypercoagulable state and be of therapeutic benefit", VOX SANGUINIS 20201201 BLACKWELL PUBLISHING LTD NLD, vol. 115, no. SUPPL 1, 1 December 2020 (2020-12-01), pages - 67 CONF, XP002803319, ISSN: 1423-0410 | [XI] JOHANSEN: "Exchange Plasmapheresis Is Effective In Removing Procoagulant Microparticles and Has Additional Therapeutic Benefit In The Treatment Of TTP | Blood | American Society of Hematology", BLOOD, vol. 122, no. 21, 1 January 2013 (2013-01-01), pages 3584, XP055788896, Retrieved from the Internet | Examination | VAN TITS L J ET AL: "Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 390, no. 1, 4 December 2009 (2009-12-04), pages 161 - 164, XP026697006, ISSN: 0006-291X, [retrieved on 20090930], DOI: 10.1016/J.BBRC.2009.09.102 DOI: http://dx.doi.org/10.1016/j.bbrc.2009.09.102 | BARSOUM A L ET AL: "Detection of glycophorin a-like glycoproteins on the surface of cultured human cells", INTERNATIONAL JOURNAL OF BIOCHEMISTRY, PERGAMON, vol. 21, no. 6, 1 January 1989 (1989-01-01), pages 635 - 643, XP025206264, ISSN: 0020-711X, [retrieved on 19890101], DOI: 10.1016/0020-711X(89)90383-2 DOI: http://dx.doi.org/10.1016/0020-711X(89)90383-2 | by applicant | KATO, G.J. ET AL., NATURE REVIEWS DISEASE PRIMERS, vol. 4, no. 1, 2018, pages 18010 - 22 | ANSTEE, D.J., VOX SANGUINIS, vol. 58, no. 1, 1990, pages 1 - 20 | ANSTEE, D.J., VOX SANGUINIS, vol. 100, no. 1, 2011, pages 140 - 149 | "UniProt", Database accession no. P02724 | HELLSTERN PSOLHEIM BG, TRANSFUS MED HEMOTHER, vol. 38, no. 1, 2011, pages 65 - 70 | OKUBO Y ET AL., VOX SANG., vol. 54, no. 2, 1988, pages 107 - 111 | MANKELOW TJ ET AL., BLOOD, vol. 126, no. 15, 2015, pages 1831 - 1834 | REID ME ET AL., TRANSFUSION CLINIQUE ET BIOLOGIQUE: JOURNAL DE LA SOCIETE FRANCAISE DE TRANSFUSION SANGUINE, vol. 4, no. 1, 1997, pages 57 - 64 | VAN TITS LJ ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 390, no. 1, 2009, pages 161 - 164 | KASAR M ET AL., J THROMB THROMBOLYSIS, vol. 38, no. 2, 2014, pages 167 - 175 | ELNASHAR, M.M., JOURNAL OF BIOMATERIALS AND NANOBIOTECHNOLOGY, vol. 1, no. 1, 2010, pages 61 - 76 | NARLA, J.MOHANDAS, N., INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol. 39, 2017, pages 47 - 52 | GALLAGHER, P.G.: "Education Program Book", vol. 1, 2005, ASH, pages: 13 - 18 | BANKS, M.SHIKLE, J., ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, vol. 142, no. 11, 2018, pages 1425 - 1427 | SHI JGILBERT GE, BLOOD, vol. 101, no. 7, 2003, pages 2628 - 2636 | WESTERMAN M ET AL., BRITISH JOURNAL OF HAEMATOLOGY, vol. 142, no. 1, 2008, pages 126 - 135 | REID ME ET AL., TRANSFUSION CLINIQUE ET BIOLOGIQUE, vol. 4, no. 1, 1997, pages 57 - 64 | SIMAK J ET AL., BRITISH JOURNAL OF HAEMATOLOGY, vol. 125, no. 6, 2004, pages 804 - 813 | LANNIGAN JERDBRUEGGER U, METHODS, vol. 112, 2017, pages 55 - 67 | RAVICHANDRAN KS, IMMUNITY, vol. 35, no. 4, 2011, pages 445 - 455 | KUYPERS FA ET AL., BLOOD, vol. 87, no. 3, 1996, pages 1179 - 1187 | KUYPERS FA ET AL., BLOOD, vol. 91, no. 8, 1998, pages 3044 - 3051 | ARRAUD N ET AL., J THROMB HAEMOST., vol. 12, no. 5, 2014, pages 614 - 627 | ANSTEE DJEDWARDS PA, EUR J IMMUNOL., vol. 12, no. 3, 1982, pages 228 - 232 | VAN TITS LJ ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 390, no. 1, 2009, pages 161 - 164 | BECKMANN R ET AL., MOL MEMBR BIOL., vol. 19, no. 3, 2002, pages 187 - 200 | WAINWRIGHT SD ET AL., BIOCHEM J., vol. 258, no. 1, 1989, pages 211 - 220 |